您当前的位置：
首页 >
文章列表页 >
Mechanism of Qizhu Kang'ai Prescription for Inhibiting Proliferation of Hepatocellular Carcinoma by Regulating Tumor Metabolic Reprogramming via PCK1/Akt/p21 Signal Axis
更新时间：2023-12-28
|

    • Mechanism of Qizhu Kang'ai Prescription for Inhibiting Proliferation of Hepatocellular Carcinoma by Regulating Tumor Metabolic Reprogramming via PCK1/Akt/p21 Signal Axis

    • “The latest research has found that Qizhu anti-cancer formula can regulate the metabolic reprogramming of liver cancer cells, inhibit cell proliferation, and provide new ideas for liver cancer treatment.”
    • Chinese Journal of Experimental Traditional Medical Formulae   Vol. 30, Issue 3, Pages: 26-36(2024)

    • DOI：10.13422/j.cnki.syfjx.20232424    

      CLC： R2-0;R22;R242;R285.5;R735.7

    • Received：21 August 2023，

      Published Online：03 November 2023，

      Published：05 February 2024

    移动端阅览

  • ZHONG Xin,HU Rui,LI Jing,et al.Mechanism of Qizhu Kang'ai Prescription for Inhibiting Proliferation of Hepatocellular Carcinoma by Regulating Tumor Metabolic Reprogramming via PCK1/Akt/p21 Signal Axis[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(03):26-36. DOI： 10.13422/j.cnki.syfjx.20232424.

  •  
  •  

0

Views

41

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Research Progress of Traditional Chinese Medicine Intervention in Malignant Tumor Metastasis Based on Metabolic Reprogramming
Compound Xishu Granules Inhibit Proliferation of Hepatocellular Carcinoma Cells by Regulating Ferroptosis
Mechanism of Treatment of Hepatocellular Carcinoma with Traditional Chinese Medicine Based on Epigenetic Regulation： A Review
Mechanism of Si Junzitang in Inhibiting Hepatocellular Carcinoma Progression Through Regulating O-GlcNAcylation of NF-κB p65 in Paracancerous Tissues
Mechanism of Inducing Ferroptosis in Hepatocellular Carcinoma Cells by Shugan Quyu Jiedu Prescription Based on p53/SLC7A11/GPX4 Pathway

Related Author

LI Hesheng
LI Chunchan
GUO Huahui
HUANG Jiasheng
LAN Congying
CHEN Penghui
HUANG Renfa
TIAN Yuan

Related Institution

Shenzhen Hospital， Guangzhou University of Chinese Medicine （ Futian ）
School of Chinese Materia Medica，Beijing University of Chinese Medicine
Beijing Institute of Traditional Chinese Medicine，Beijing University of Chinese Medicine
School of Life Sciences，Beijing University of Chinese Medicine
Artemisinin Research Center and Institute of Chinese Materia Medica， China Academy of Chinese Medical Sciences
0